Smith and Nephew - strong Q4 showing23 Apr 2026 15:27
.wealthoracle.co.uk/companies/SN.
Smith and Nephew posted impressive FY 25 results helped along by a strong Q4 showing. The Group delivered a strong finish to 2025, marking the successful completion of its multi-year 12-Point Plan transformation and setting the stage for accelerated growth under its new RISE strategy. Fourth-quarter revenue rose 8.3% reported (6.2% underlying) to $1.7 billion, bringing full-year revenue to $6.16 billion, up 6.1% reported and 5.3% underlying. Growth was broad-based across Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management, with newer product launches contributing meaningfully to performance. Profitability improved materially. Trading profit increased 15.5% to $1.21 billion, with trading margin expanding 160 basis points to 19.7%. Reported operating profit rose 20.7% to $794 million, reflecting operational leverage and productivity gains delivered through the transformation program. Earnings per share showed strong momentum, with adjusted EPS up 21% to 102.0 cents and reported EPS up 52.8% to 72.1 cents. The balance sheet remains solid, with adjusted net debt/EBITDA at 1.7x. This enabled completion of a $500 million share buyback in 2H 2025 and a 4.3% increase in the full-year dividend. Strategically, management declared the 12-Point Plan complete, citing 5.7% revenue CAGR since 2022, 240bps of trading margin expansion, and a fifteen-fold increase in free cash flow. The newly launched RISE strategy (Reach, Innovation, Scale, Execute) aims to accelerate growth and returns through product innovation, portfolio optimization, and operational efficiency. The acquisition of Integrity....
.wealthoracle.co.uk/companies/SN.